Press Release

Ref: MHL/Sec&Legal/2026-27/34 August 04, 2026 BSE Limited National Stock Exchange of India Limited Scrip Code: 542650 Scrip Symbol: METROPOLIS Dear Sir/Madam, Sub: Press Release Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed herewith is the Press Release as mentioned below: “Metropolis Healthcare reports strong Q1FY27 performance, with revenue up 17% to ₹450 crore and EBITDA up 27% YoY.” You are requested to take the above information on record. Thanking you, Yours faithfully, For Metropolis Healthcare Limited Kamlesh C Kulkarni Head – Legal & Secretarial Encl.: a/a PRESS RELEASE Metropolis Healthcare reports strong Q1FY27 performance, with revenue up 17% to ₹450 crore and EBITDA up 27% YoY. Mumbai, India, 4th August 2026: Ameera Shah-led Metropolis Healthcare Limited (NSE: METROPOLIS | BSE: 542650), India’s second-largest and the most respected pathology laboratory chain, today announced its unaudited consolidated financial results for the quarter ended June 30th, 2026. REVENUE EBITDA PAT INR 450 Cr INR 113 Cr INR 57 Cr ▲ 17% YoY ▲ 27% YoY ▲ 26% YoY Q1FY27 – Financial & Operational Highlights • Patient volume grew 10% YoY, while test volume increased 11% YoY, reflecting sustained demand, deeper market penetration and the continued shift towards trusted diagnostic chains. • B2C revenue grew 18% YoY, driven by strong brand pull, targeted micro-marketing and expanding digital engagement. B2B revenue increased 15% YoY, supported by improving business quality and a broader clinician and institutional network. • TruHealth revenue grew 22% YoY to INR 81 crore (18% of segment mix), while Specialty revenue increased 17% YoY to INR 178 crore (40% of segment mix), strengthening the portfolio mix. Premium TruHealth packages grew over 50%, while radiology-integrated wellness packages increased by more than 40%. • Revenue per Patient (RPP) increased 6% YoY, while Revenue per Test (RPT) improved 5% YoY, supported by a richer test mix and higher contribution from specialised diagnostics. • Tier III cities remained the fastest-growing markets, with revenue increasing around 25% YoY, compared with 11% growth in Tier I and 14% in Tier II, highlighting the significant growth opportunity beyond large metros. "The diagnostics industry is consolidating around trusted, science-led providers as patients increasingly prioritise quality, accuracy and specialised care. Our investments in scientific innovation, strategic acquisitions and network expansion continue to strengthen Metropolis' leadership across key markets, particularly in North India, while broadening our differentiated diagnostics offering. This quarter, we delivered 17% revenue growth through higher volumes without any price increase, reflecting the continued confidence that patients and clinicians place in the Metropolis brand. As we continue to scale, our focus remains on making high-quality diagnostics more accessible while creating sustainable long-term value for all our stakeholders." ~ Ms. Ameera Shah, Promoter and Executive Chairperson, Metropolis Healthcare Limited. “Our strong start to the year reflects disciplined execution and the resilience of our business model. Healthy growth in patient and test volumes, together with a 210-basis point expansion in EBITDA margin, demonstrates the quality of our growth and the scalability of our operating model. Continued momentum in Specialty diagnostics and TruHealth reflects the strength of our portfolio. We remain focused on enhancing productivity, driving operational excellence and delivering sustainable, profitable growth.”~ Mr. Surendran Chemmenkotil, Managing Director, Metropolis Healthcare Limited. Financial Results Snapshot – Q1FY27 In INR Crs. Q1FY27 Q1FY26 Y-o-Y Revenue from operations 450.2 386.1 16.6% EBITDA 113.2 89.1 27.1% EBITDA Margin (%) 25.2% 23.1% 210 bps Profit After Tax 56.9 45.2 25.8% PAT Margin (%) 12.6% 11.7% 90 bps About Metropolis Healthcare Limited: Established in 1981, Metropolis Healthcare Limited is India’s second-largest diagnostic chain, led by visionary leader Ms. Ameera Shah. With over four decades of excellence, Metropolis has been a pioneer in delivering best-in-class diagnostic services to patients, healthcare providers, and corporates across India and Africa. The company’s extensive footprint spans 28 states, 7 Union Territories, and over 750+ towns in India, supported by a robust network of more than 209 laboratories, 5000 plus service network, and over 10,000 touchpoints. Each year, Metropolis serves millions of individuals by providing actionable health insights that empower better clinical outcomes. Metropolis offers a comprehensive range of more than 4,500 tests and profiles, including advanced tests for diagnosing cancer, neurological disorders, infectious diseases, and various genetic abnormalities. The company’s commitment to quality and accuracy is reinforced by its consistent CAP proficiency score of over 99.99% for the past decade, placing it among the top 1% of laboratories worldwide for quality assurance. The Metropolis philosophy is built on the pillars of technological superiority, a warm, patient-centric approach, and reliable diagnostic reports. For more information, please visit www.metropolisindia.com or click on Twitter, Facebook, or LinkedIn Safe harbor statement: Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors. For further details, please contact: Investor Relations Advisors: Strategic Growth Company: Metropolis Healthcare Ltd. Advisors Pvt. Ltd. CIN: L73100MH2000PLC192798 CIN: U74140MH2010PTC204285 Mr. Jeyasingh Balakrishnan Mr. Shogun Jain / Mr. Sagar Shroff Head – Corporate Communications & CSR +91 77383 77756 / +91 98205 19303 +91 9833836185 Email: shogun.jain@sgapl.net/ Email: jeyasingh.b@metropolisindia.com sagar.shroff@sgapl.net